 phase II studi day cisplatin recombin interferon advanc non-smal cell lung cancer preclin data studi human lung cancer cytotox effect cisplatin alpha-interferon observ author phase II trial advanc non-smal cell lung cancer nsclc cisplatin cycl divid day day schedul day interferon dose unit time week minimum month between januari septemb patient respons toxic system mountain patient stage IV diseas stage iiib diseas stage iiia diseas express neuron-specif enolas nse possibl relationship treatment respons respons rate confid interv CI respond posit nse posit averag cycl mean dose intens dose cisplatin dose interferon standard scale interferon toxic hematolog renal system side effect signific advanc nsclc addit interferon cisplatin-induc respons rate studi real valu chemotherapi respons tumor posit immunoreact neural marker nse